OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO) today is reporting financial results for the year ended December 31, 2015, and providing a business update.
Business Update
2015 has been a year of change for Transgenomic as the Company has worked to realign its core activities around the commercialization of ICE COLD-PCR™ (ICP), an innovative technology that enables the use of DNA liquid biopsies for better, safer and less expansive diagnosis and treatment of many diseases. Broader commercialization of ICP is expected to provide a foundation for expansion of the licensing and partnering strategy we are pursuing in order to maximize the value of this broadly enabling technology. As a part of our focus on ICP, we have worked to exit lower growth legacy businesses.
Business Update
2015 has been a year of change for Transgenomic as the Company has worked to realign its core activities around the commercialization of ICE COLD-PCR™ (ICP), an innovative technology that enables the use of DNA liquid biopsies for better, safer and less expansive diagnosis and treatment of many diseases. Broader commercialization of ICP is expected to provide a foundation for expansion of the licensing and partnering strategy we are pursuing in order to maximize the value of this broadly enabling technology. As a part of our focus on ICP, we have worked to exit lower growth legacy businesses.
